Predicting early tumor recurrence in esophageal cancer patients
Official title: Predicting Postoperative Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma
Run by City of Hope Medical Center · NCT06476067 · Data updated 2026-11-12
This study is testing if certain DNA patterns from tissue samples can help predict if esophageal cancer will come back early in patients who have had surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | City of Hope Medical Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Nagoya, Aichi-ken and 1 other locations) |
| Status | Recruiting |
| Started | January 1, 2006 |
| Main results expected | June 18, 2028 |
| Study ends | June 18, 2028 |
| Registry record updated | July 13, 2026 |
| Trial ID | NCT06476067 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with histologically confirmed ESCC who have undergone complete esophagectomy without prior chemotherapy or radiotherapy.
✕Probably not a fit
Patients with multiple cancers or those lacking clinical information within two years of surgery may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on patients with esophageal squamous cell carcinoma (ESCC) who have undergone surgery. The researchers aim to identify biomarkers, specifically DNA methylation patterns, that can predict early tumor recurrence by analyzing whole genome DNA methylation from surgical specimens. Given that approximately 40% of patients experience recurrence within two years post-surgery, this study seeks to improve prognostic capabilities and potentially guide further treatment decisions. The study will involve patients who have had complete esophagectomy and have available tissue samples for analysis.
Why it matters
Potential benefit: If successful, this study could lead to improved prediction of tumor recurrence, allowing for timely interventions and better patient outcomes.
How similar studies have gone: While the use of DNA methylation as a biomarker is gaining traction, this specific approach to predict early recurrence in ESCC is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients who had histologically confirmed ESCC. 2. Patients who had undergone only complete esophagectomy with radical lymph node dissection without chemotherapy or radiotherapy before or after surgery. 3. Patients for whom tissue samples are available 4. Patients who were followed-up completely, with information on observation periods of at least 2 years after surgery. 5. Written informed consent following full study information is provided to the patient. Exclusion Criteria: 1. Patients lacking clinical information within 2 years of surgery. 2. Patients with multiple cancers.
Where it's running
-
Nagoya University
Nagoya, Aichi-ken, Japan Recruiting -
Yamanashi Universiy
Chūō, Yamanashi, Japan Recruiting
Study contacts
- Principal investigator: Koichi Takiguchi, PhD — City of Hope Medical Center
- Study coordinator: Ajay Goel, PhD
- Email: AJGOEL@COH.ORG
- Phone: 6262183452
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PF-08098488 in adults with advanced solid tumors
This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.
-
Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer
This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.
-
MGC030 in adults with advanced solid tumors
This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
TS-104: a first-in-human, dose-escalation study for advanced solid tumors
This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.
-
First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors
This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.